Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
- 28 September 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Neuropsychopharmacology
- Vol. 37 (1), 16-42
- https://doi.org/10.1038/npp.2011.199
Abstract
Muscarinic and nicotinic acetylcholine (ACh) receptors (mAChRs and nAChRs) are emerging as important targets for the development of novel treatments for the symptoms associated with schizophrenia. Preclinical and early proof-of-concept clinical studies have provided strong evidence that activators of specific mAChR (M1 and M4) and nAChR (α7 and α2β4) subtypes are effective in animal models of antipsychotic-like activity and/or cognitive enhancement, and in the treatment of positive and cognitive symptoms in patients with schizophrenia. While early attempts to develop selective mAChR and nAChR agonists provided important preliminary findings, these compounds have ultimately failed in clinical development due to a lack of true subtype selectivity and subsequent dose-limiting adverse effects. In recent years, there have been major advances in the discovery of highly selective activators for the different mAChR and nAChR subtypes with suitable properties for optimization as potential candidates for clinical trials. One novel strategy has been to identify ligands that activate a specific receptor subtype through actions at sites that are distinct from the highly conserved ACh-binding site, termed allosteric sites. These allosteric activators, both allosteric agonists and positive allosteric modulators, of mAChR and nAChR subtypes demonstrate unique mechanisms of action and high selectivity in vivo, and may provide innovative treatment strategies for schizophrenia.Keywords
This publication has 327 references indexed in Scilit:
- Insights into the neurodevelopmental origin of schizophrenia from postmortem studies of prefrontal cortical circuitryInternational Journal of Developmental Neuroscience, 2011
- Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in SchizophreniaBiological Psychiatry, 2011
- Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulatorsBioorganic & Medicinal Chemistry Letters, 2010
- A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonistsBiochemical Pharmacology, 2009
- Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity α4β2 subunit combinationBiochemical Pharmacology, 2009
- TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophreniaBiochemical Pharmacology, 2009
- nAChR agonist-induced cognition enhancement: Integration of cognitive and neuronal mechanismsBiochemical Pharmacology, 2009
- Differential Regulation of α7 Nicotinic Receptor Gene (CHRNA7) Expression in Schizophrenic SmokersJournal of Molecular Neuroscience, 2009
- Stimulation of the α4β2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 miceBrain Research, 2008
- Cholinergic neurons of the laterodorsal tegmental nucleus: Efferent and afferent connectionsJournal of Comparative Neurology, 1986